Stock Events

Stock Events

Search...

Abivax

€10.6

40

-€0.14-1.3% Today

Statistics

Day High

10.6

Day Low

10.6

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

685.8M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

9SepExpected

Q1 2024

Q2 2024

-1.84

-1.52

-1.19

-0.87

Expected EPS

-1.3330095161659226

Actual EPS

-1.26182970264

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2X1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that competes with Abivax in the development of antiviral drugs, including treatments for HIV, which is a focus area for Abivax.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in creating antiviral treatments and therapies for infectious diseases, competing directly with Abivax's efforts in HIV and other viral infections.

Merck & Co., Inc. is a global healthcare company that develops antiviral drugs, including therapies for HIV/AIDS, positioning it as a competitor to Abivax.

GlaxoSmithKline plc focuses on developing and marketing vaccines and medications for HIV, directly competing with Abivax's research and development in HIV treatments.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical division Janssen, works on developing treatments for infectious diseases, including HIV, making it a competitor to Abivax.

AbbVie Inc. competes in the area of antiviral research, with a focus on therapies for HIV, hepatitis, and other viral infections, areas that Abivax is also targeting.

Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products, including antiviral drugs, competing with Abivax in the infectious disease space.

Bristol-Myers Squibb

Bristol Myers Squibb is engaged in the discovery and development of prescription medicines for various diseases, including HIV/AIDS, making it a direct competitor to Abivax.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is known for its work in biotechnology and the development of medicines for infectious diseases, competing with Abivax in the biopharmaceutical field.

Novartis AG is a global healthcare company that researches and develops treatments for a wide range of diseases, including viral infections, competing with Abivax in the pharmaceutical and healthcare market.

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Show more...

CEO

Mr. Marc M. P. de Garidel M.B.A.

Employees

61

Country

FR

ISIN

FR0012333284

WKN

000A14UQC

Listings